Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of “Moderate Buy” from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $21.00.

Several equities analysts have recently weighed in on TLX shares. Wall Street Zen lowered shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. UBS Group cut their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, December 22nd. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently modified their holdings of TLX. Rhumbline Advisers lifted its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $213,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $217,000. JPMorgan Chase & Co. acquired a new stake in shares of Telix Pharmaceuticals during the 3rd quarter worth approximately $243,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Telix Pharmaceuticals in the second quarter valued at approximately $297,000.

Telix Pharmaceuticals Stock Performance

TLX opened at $7.73 on Wednesday. The stock’s fifty day simple moving average is $8.56 and its 200 day simple moving average is $10.46. Telix Pharmaceuticals has a 1-year low of $7.31 and a 1-year high of $30.36.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.